

Metabolism of Linoleic Acid by Human Gut Bacteria: Different Routes for Biosynthesis of Conjugated Linoleic Acid[∇]

Estelle Devillard, Freda M. McIntosh, Sylvia H. Duncan, and R. John Wallace*

Gut Health Division, Rowett Research Institute, Greenburn Road, Bucksburn, Aberdeen, AB21 9SB, United Kingdom

Received 28 August 2006/Accepted 26 December 2006

A survey of 30 representative strains of human gram-positive intestinal bacteria indicated that *Roseburia* species were among the most active in metabolizing linoleic acid (*cis*-9,*cis*-12-18:2). Different *Roseburia* spp. formed either vaccenic acid (*trans*-11-18:1) or a 10-hydroxy-18:1; these compounds are precursors of the health-promoting conjugated linoleic acid *cis*-9,*trans*-11-18:2 in human tissues and the intestine, respectively.

Linoleic acid (LA) (*cis*-9,*cis*-12-18:2) is metabolized in the human colon via conjugated linoleic acids (CLA) (mainly *cis*-9,*trans*-11-18:2) to vaccenic acid (VA) (*trans*-11-18:1) (both of the latter compounds are considered to be beneficial for health [5, 11, 27, 28, 31, 41]) and then to stearic acid (18:0) (17, 26). A similar pathway occurs in the rumen (12, 20), where this process, commonly known as biohydrogenation, has important implications for the fatty acid composition of meat and milk (22, 38). The microbiology of biohydrogenation in the rumen has received a great deal of attention (12, 32, 40, 42), but similar investigations have not been carried out for the human intestinal microbiota. Therefore, the aims of the present study were to identify human gut bacteria that can perform fatty acid biohydrogenation and to assess their likely importance in the mixed intestinal ecosystem. We found that *Roseburia* spp. were probably the most important organisms; some *Roseburia* species metabolized LA by the same pathway found in ruminal bacteria (20, 32), while others formed a hydration product that is a precursor of CLA in the mixed community.

Thirty bacterial strains (2 lactobacilli, 1 lactococcus, 5 propionibacteria, 3 bifidobacteria, and 19 strains of the low-G+C-content *Clostridium* cluster) isolated from or related to bacteria found in the human large intestine were studied to determine their ability to metabolize LA (Table 1). The bacteria were grown either in the liquid form of anaerobic basal M2 medium (13) or in the same medium supplemented with 50 μ g/ml LA. For labeling experiments the medium was prepared using enough deuterium oxide to provide around 50% enrichment of the medium water. The linoleate isomerase activity in bacteria grown on unsupplemented M2 medium was determined by the method described by Wąsowska et al. (43). The methods used for extraction and derivatization of the total fatty acids to fatty acid methyl esters (FAME) and the identification methods were similar to the methods described by Devillard et al. (7). In order to determine the fate of the hydroxy-18:1 fatty acid (HFA) produced by some of the *Roseburia* isolates, *Roseburia intestinalis* L1-952 was grown in M2 medium containing 50 μ g/ml LA, the culture was centrifuged

(10,000 \times g, 10 min, 4°C), and the supernatant was used to prepare a modified M2 medium enriched in HFA. This medium was inoculated with freshly voided human feces from two omnivorous volunteers consuming a Western diet, which had been diluted (0.2 g in 1 ml) in sterile anaerobic 0.1 M potassium phosphate buffer (pH 7.0). Duplicate aliquots of each fecal sample were removed after different times for fatty acid determination for up to 72 h.

The linoleate isomerase activity was >10 nmol CLA formed (mg protein)⁻¹ min⁻¹ in 8 of the 30 isolates (Table 1), and *Butyrivibrio fibrisolvens* 16.4 and two strains of *Roseburia inulinivorans* (A2-194 and L1-83) exhibited the highest activity. When inoculated into medium containing LA, most of the 30 strains showed a lag time before they started to grow (Table 1). The same eight isolates that had high levels of isomerase activity also metabolized LA most extensively (Table 1). The final products for these strains were VA for the *Roseburia* and *B. fibrisolvens* isolates, a mixture of CLA (mainly *cis*-9,*trans*-11-18:2, *trans*-9,*trans*-11-18:2, and *trans*-10,*cis*-12-18:2) for *Propionibacterium freudenreichii* subsp. *shermani*, and *cis*-9,*trans*-11-18:2 and *trans*-9,*trans*-11-18:2 for *Bifidobacterium breve* (Table 1). Thus, it appears that whereas other species produced a mixture of CLA products, bacteria belonging to *Clostridium* cluster XIVa formed one product, either VA or HFA. Thirteen strains, belonging to both phylogenetic groups, metabolized LA (range, 26% to 88%) despite their low linoleate isomerase activity (Table 1). Gas chromatography traces indicated that all these strains produced the same compound, which was subsequently identified by gas chromatography-mass spectrometry (Fig. 1A). The main fragmentation in mass spectrometry led to the formation of ions at *m/z* 169 and 201, which are characteristic of a 10-HFA with the first 10 bonds saturated. When *R. intestinalis* L1-952 was grown in the presence of 50 μ g/ml LA and deuterium oxide, the two major peaks were shifted to ions at *m/z* 171 and 203 (Fig. 1B). This shift corresponded to an addition of deuterium atoms at the double bond between carbons 9 and 10, suggesting that hydration occurred on this double bond (Fig. 1B). The location of the double bond could not be determined by analysis of the FAME. However, the signature masses at *m/z* 201 and 294 identified in 10-hydroxy-*cis*-12-18:1 by Schroepfer et al. (37) were present in the FAME spectrum. This information, together with purely biochemical considerations and comparison

* Corresponding author. Mailing address: Rowett Research Institute, Bucksburn, Aberdeen, AB21 9SB, United Kingdom. Phone: 44(0)1224-716656. Fax: 44(0)1224-716687. E-mail: john.wallace@rowett.ac.uk.

[∇] Published ahead of print on 5 January 2007.

TABLE 1. Metabolism of linoleic acid by different bacterial species

| Strain | Group | Source (reference) | Linoleate isomerase activity (nmol CLA mg protein ⁻¹ min ⁻¹) | Lag time (h) | % LA metabolized ^a | Main products formed ^a |
|--|----------------|----------------------------|---|--------------|-------------------------------|-----------------------------------|
| <i>Lactobacillus reuteri</i> DSM 20016 ^T | Firmicutes | Human adult intestine (18) | 0.7 ± 0.1 | 0 | 28 ± 3 | HFA |
| <i>Lactobacillus delbrueckii</i> subsp. <i>bulgaricus</i> DSM 20081 ^T | Firmicutes | Bulgarian yoghurt (39) | 0.6 ± 0.1 | 72 | 14 ± 5 | None |
| <i>Lactococcus lactis</i> subsp. <i>lactis</i> DSM 20729 | Firmicutes | Swiss cheese (35) | 0.0 ± 0.0 | 0 | 44 ± 6 | HFA |
| <i>Propionibacterium freudenreichii</i> DSM 20271 ^T | Actinobacteria | Swiss cheese (16) | 1.2 ± 0.1 | 72 | 11 ± 1 | None |
| <i>Propionibacterium freudenreichii</i> subsp. <i>shermani</i> DMS 20270 | Actinobacteria | Cheese (36) | 14.3 ± 1.1 | 24 | 96 ± 9 | CLA (c9t11, t9t11, t10c12) |
| <i>Propionibacterium freudenreichii</i> subsp. <i>shermani</i> DMS 4902 ^T | Actinobacteria | Unknown (16) | 17.0 ± 1.7 | 72 | 85 ± 7 | CLA (c9t11, t9t11, t10c12) |
| <i>Propionibacterium jensenii</i> DSM 20274 | Actinobacteria | Silage (36) | 2.4 ± 0.1 | 0 | 12 ± 1 | None |
| <i>Propionibacterium thoenii</i> DSM 20276 ^T | Actinobacteria | Emmental cheese (36) | 3.5 ± 0.2 | 48 | 31 ± 9 | HFA |
| <i>Bifidobacterium adolescentis</i> NCFB 2204 | Actinobacteria | Human adult intestine (6) | 0.7 ± 0.0 | 24 | 68 ± 6 | HFA |
| <i>Bifidobacterium breve</i> NCFB 2258 | Actinobacteria | Human infant intestine (6) | 15.4 ± 0.9 | 0 | 95 ± 8 | CLA (c9t11, t9t11) |
| <i>Bifidobacterium infantis</i> NCFB 2256 | Actinobacteria | Human infant intestine (6) | 3.6 ± 0.2 | 24 | 79 ± 4 | HFA |
| <i>Faecalibacterium prausnitzii</i> L2-6 | Cluster IV | Human feces (3) | 0.5 ± 0.0 | 48 | 32 ± 9 | HFA |
| <i>Eubacterium siraeum</i> DSM 15702 ^T | Cluster IV | Human feces (29) | 2.7 ± 0.0 | 24 | 26 ± 5 | HFA |
| <i>Anaerostipes caccae</i> L1-92 ^T | Cluster XIVa | Human feces (24) | 0.0 ± 0.0 | 0 | 15 ± 4 | None |
| <i>Eubacterium halli</i> L2-7 | Cluster XIVa | Human feces (24) | 3.5 ± 0.5 | 24 | 10 ± 2 | None |
| <i>Eubacterium ventriosum</i> L2-12 | Cluster XIVa | Human feces (3) | 0.0 ± 0.0 | 0 | 14 ± 5 | None |
| <i>Eubacterium ruminantium</i> L2-50 | Cluster XIVa | Human feces (24) | 0.0 ± 0.0 | 24 | 38 ± 3 | HFA |
| <i>Eubacterium rectale</i> T1-815 | Cluster XIVa | Human feces (24) | 1.3 ± 0.0 | 24 | 11 ± 2 | None |
| <i>Eubacterium rectale</i> A1-86 | Cluster XIVa | Human feces (24) | 3.5 ± 0.2 | 24 | 15 ± 1 | None |
| <i>Eubacterium rectale</i> M104/1 | Cluster XIVa | Human feces (3) | 2.4 ± 0.2 | 24 | 10 ± 2 | None |
| <i>Roseburia inulinivorans</i> A2-194 ^T | Cluster XIVa | Human feces (8) | 23.3 ± 1.6 | 24 | 100 ± 6 | VA |
| <i>Roseburia inulinivorans</i> L1-83 | Cluster XIVa | Human feces (8) | 30.0 ± 2.3 | 24 | 100 ± 4 | VA |
| <i>Roseburia hominis</i> A2-183 ^T | Cluster XIVa | Human feces (8) | 10.6 ± 0.8 | 0 | 100 ± 6 | VA |
| <i>Roseburia hominis</i> A2-181 | Cluster XIVa | Human feces (8) | 11.6 ± 0.6 | 0 | 100 ± 8 | VA |
| <i>Roseburia intestinalis</i> L1-82 ^T | Cluster XIVa | Human feces (8) | 0.4 ± 0.0 | 24 | 84 ± 11 | HFA |
| <i>Roseburia intestinalis</i> L1-952 | Cluster XIVa | Human feces (8) | 0.5 ± 0.1 | 24 | 85 ± 13 | HFA |
| <i>Roseburia faecis</i> M6/1 | Cluster XIVa | Human feces (8) | 0.9 ± 0.1 | 24 | 86 ± 9 | HFA |
| <i>Roseburia faecis</i> M88/1 | Cluster XIVa | Human feces (8) | 0.9 ± 0.0 | 24 | 76 ± 8 | HFA |
| <i>Roseburia faecis</i> M72/1 ^T | Cluster XIVa | Human feces (8) | 1.0 ± 0.0 | 24 | 88 ± 12 | HFA |
| <i>Butyrivibrio fibrisolvens</i> 16.4 | Cluster XIVa | Human feces (24) | 45.3 ± 3.1 | 24 | 100 ± 4 | VA |

^a When the optical density at 600 nm of a culture reached 0.6, fatty acids were extracted from the culture, the percentages of linoleic acid metabolized were calculated, and the products formed during growth were identified. These analyses were conducted in triplicate.

of the elution time of the FAME with that of ricinoleic acid (12-hydroxy-*cis*-9-18:1), indicated that the product was most likely 10-hydroxy-*cis*-12-18:1.

Modified M2 medium prepared from the culture supernatant of *R. intestinalis* L1-952 initially contained 5 µg/ml LA and 25 µg/ml HFA. The main fatty acids produced during incubation with diluted feces were *cis*-9,*trans*-11-18:2, VA, and stearic acid (Fig. 2). After a few hours, LA was almost completely metabolized, but the synthesis of CLA, VA, and stearic acid continued and corresponded to the disappearance of HFA (Fig. 2). Thus, we concluded that HFA is a precursor of *cis*-9,*trans*-11-18:2 in the mixed community. None of the pure cultures examined metabolized the HFA further.

Animal studies and clinical trials have indicated that CLA may be useful in improving human health (5, 27, 31). The uptake of CLA formed in the intestine seems to be minor (17).

However, local effects on gut tissue might be anticipated. It is now well established that CLA have antiproliferative and anti-inflammatory effects on colonocytes (4, 19), so provision of CLA in the intestinal lumen could be considered beneficial, particularly for inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease (10). Bacteria from other ecosystems and from food products which are also found in the human gut, including strains of *Lactobacillus*, *Propionibacterium*, and *Bifidobacterium* (1, 6, 15, 23, 33, 34), have been known for some time to possess the ability to generate CLA. For the first time, we found here that the more abundant bacterial species belonging to clostridial clusters IV and XIVa also metabolize LA at some of the highest rates of all bacteria investigated, forming products that can be precursors of CLA (Fig. 3). Given the greater abundance of *Clostridium*-like bacteria in the human intestinal microbiota (9)—the numbers of lactobacilli, propionibacteria, and bifidobacteria are low, less




FIG. 1. Mass spectra of the methyl ester of the HFA produced by 13 of the 30 bacterial strains studied here when they were incubated with linoleic acid. (A) Mass spectrum obtained with the unlabeled FAME derivative. (B) Mass spectrum obtained with the FAME derivative obtained from cultures containing deuterium oxide, showing peaks at m/z 160 to 210, where the two characteristic fragments of HFA are present.

than 5% of the total microbiota (2, 21)—it may be deduced that LA metabolism by this major group is quantitatively more important than LA metabolism by the *Lactobacillus*, *Propionibacterium*, and *Bifidobacterium* groups.

The discovery that HFA is a precursor of *cis*-9,*trans*-11-18:2 in the mixed intestinal community is also new, leading to the likely scheme of CLA formation shown in Fig. 3. Similar importance of HFA was proposed for a *Lactobacillus* sp., involv-




FIG. 2. Metabolism of HFA (■) and LA (◆) and formation of the products CLA (△), VA (○), and stearic acid (□) by mixed fecal flora from volunteer 1 (A) and from volunteer 2 (B). The values are the means of duplicates and are expressed in µg of fatty acid/ml of fecal suspension.

ing a hydration/dehydration process (30). No similar role for HFA has been postulated for bacteria in the rumen, where biohydrogenation is a quantitatively very important activity (12, 32).

The final product of LA metabolism by mixed fecal microbiota was shown here to be stearic acid, as shown previously by Howard

and Henderson (14), yet none of the strains tested here produced stearate from LA (Fig. 3). Searching for stearate producers in the rumen has been difficult, largely because these organisms are extraordinarily sensitive to the toxic effects of unsaturated fatty acids (25, 42). The same may be true of human intestinal bacteria. Thus, stearate producers and the species that convert HFA to




FIG. 3. Proposed pathways of LA metabolism by bacterial species isolated from the human gut. The open arrows represent the bacterial activity of *Lactobacillus*, *Propionibacterium*, and *Bifidobacterium* species leading to the formation of CLA. The shaded arrows represent the bacterial activity of some *Lactobacillus*, *Propionibacterium*, and *Bifidobacterium* species and some *Clostridium* species belonging to clusters IV (e.g., *Eubacterium siraeum*) and XIVa (e.g., *R. intestinalis* and *Roseburia faecis*) leading to the formation of HFA. The solid arrows represent the bacterial activity of *Clostridium*-like bacteria belonging to cluster XIVa leading to the formation of VA (e.g., *Roseburia hominis* and *R. inulinivorans*). The dotted arrows represent activities observed in fecal microbiota for which the responsible bacterial species are still unknown.

CLA, both potentially very important reactions in the mixed ecosystem of the human intestine, remain to be identified.

The Rowett Research Institute receives funding from the Scottish Executive Environmental and Rural Affairs Department.

We thank David Brown, Graham Calder, and Maureen Annand for technical help and expertise. We thank Kevin Shingfield and William Christie for advice on fatty acid analysis. We are grateful to Harry Flint for helpful criticism of the manuscript.

REFERENCES

- Alonso, L., E. P. Cuesta, and S. E. Gilliland. 2003. Production of free conjugated linoleic acid by *Lactobacillus acidophilus* and *Lactobacillus casei* of human intestinal origin. *J. Dairy Sci.* **86**:1941–1946.
- Aminov, R. I., A. W. Walker, S. H. Duncan, H. J. M. Harmsen, G. W. Welling, and H. J. Flint. 2006. Molecular diversity, cultivation, and improved fluorescent in situ hybridization detection of a dominant group of human gut bacteria related to *Roseburia* and *Eubacterium rectale*. *Appl. Environ. Microbiol.* **72**:6371–6376.
- Barcenilla, A., S. E. Pryde, J. C. Martin, S. H. Duncan, C. S. Stewart, C. Henderson, and H. J. Flint. 2000. Phylogenetic relationships of butyrate-producing bacteria from the human gut. *Appl. Environ. Microbiol.* **66**:1654–1661.
- Bassaganya-Riera, J., K. Reynolds, S. Martino-Catt, Y. Cui, L. Hennighausen, F. Gonzalez, J. Rohrer, A. U. Benninghoff, and R. Hontecillas. 2004. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. *Gastroenterology* **127**:777–791.
- Belury, M. A. 2002. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. *Annu. Rev. Nutr.* **22**:505–531.
- Coakley, M., R. P. Ross, M. Nordgren, G. Fitzgerald, R. Devery, and C. Stanton. 2003. Conjugated linoleic acid biosynthesis by human-derived *Bifidobacterium* species. *J. Appl. Microbiol.* **94**:138–145.
- Devillard, E., F. M. McIntosh, C. J. Newbold, and R. J. Wallace. 2006. Rumen ciliate protozoa contain high concentrations of conjugated linoleic acids and vaccenic acid, yet do not hydrogenate linoleic acid or desaturate stearic acid. *Br. J. Nutr.* **96**:697–704.
- Duncan, S. H., R. I. Aminov, K. P. Scott, P. Louis, T. B. Stanton, and H. J. Flint. 2006. Proposal of *Roseburia faecis* sp. nov., *Roseburia hominis* sp. nov., and *Roseburia inulinivorans* sp. nov., based on isolates from human feces. *Int. J. Syst. Evol. Microbiol.* **56**:2437–2441.
- Eckburg, P. B., E. M. Bik, C. N. Bernstein, E. Purdom, L. Dethlefsen, M. Sargent, S. R. Gill, K. E. Nelson, and D. A. Relman. 2005. Diversity of the human intestinal microbial flora. *Science* **308**:1635–1638.
- Greicius, G., V. Arulampalam, and S. Pettersson. 2004. A CLA's act: feeding away inflammation. *Gastroenterology* **127**:994–996.
- Ha, Y. L., N. K. Grimm, and M. W. Pariza. 1987. Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid. *Carcinogenesis* **8**:1881–1887.
- Harfoot, C. G., and G. P. Hazlewood. 1997. Lipid metabolism in the rumen, p. 348–426. In P. N. Hobson and C. S. Stewart (ed.), *The rumen microbial ecosystem*. Chapman & Hall, London, United Kingdom.
- Hobson, P. N. 1969. Rumen bacteria. *Methods Microbiol.* **3B**:133–149.
- Howard, F. A. C., and C. Henderson. 1999. Hydrogenation of polyunsaturated fatty acids by human colonic bacteria. *Lett. Appl. Microbiol.* **29**:193–196.
- Jiang, J., L. Bjorck, and R. Fonden. 1998. Production of conjugated linoleic acid by dairy starter cultures. *J. Appl. Microbiol.* **85**:95–102.
- Johnson, J. L., and C. S. Cummins. 1972. Cell wall composition and deoxyribonucleic acid similarities among the anaerobic coryneforms, classical propionibacteria, and strains of *Arachnia propionica*. *J. Bacteriol.* **109**:1047–1066.
- Kamlage, B., L. Hartmann, B. Gruhl, and M. Blaut. 1999. Intestinal microorganisms do not supply associated gnotobiotic rats with conjugated linoleic acid. *J. Nutr.* **129**:2212–2217.
- Kandler, O., K. O. Stetter, and R. Köhl. 1980. *Lactobacillus reuteri* sp. nov., a new species of heterofermentative lactobacilli. *Zentbl. Bakteriell. Hyg. Abt. I Orig. Reihe C* **1**:264–269.
- Kemp, M. Q., B. D. Jeffy, and D. F. Romagnolo. 2003. Conjugated linoleic acid inhibits cell proliferation through a p53-dependent mechanism: effects on the expression of G1-restriction points in breast and colon cancer cells. *J. Nutr.* **133**:3670–3677.
- Kepler, C. R., K. P. Hirons, J. J. McNeill, and S. B. Tove. 1966. Intermediates and products of the biohydrogenation of linoleic acid by *Butyrivibrio fibrisolvens*. *J. Biol. Chem.* **241**:1350–1354.
- Lay, C., M. Sutren, V. Rochet, K. Saunier, J. Dore, and L. Rigottier-Gois. 2005. Design and validation of 16S rRNA probes to enumerate members of the *Clostridium leptum* subgroup in human fecal microbiota. *Environ. Microbiol.* **7**:933–946.
- Lin, H., T. D. Boylston, M. J. Chang, L. O. Lueddecke, and T. D. Shultz. 1995. Survey of the conjugated linoleic acid contents of dairy products. *J. Dairy Sci.* **78**:2358–2365.
- Lin, T. Y., C. W. Lin, and C. H. Lee. 1999. Conjugated linoleic acid concentration as affected by lactic cultures and added linoleic acid. *Food Chem.* **67**:1–5.
- Louis, P., S. H. Duncan, S. I. McCrae, J. Millar, M. S. Jackson, and H. J. Flint. 2004. Restricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colon. *J. Bacteriol.* **186**:2099–2106.
- Maia, M. R. G., L. C. Chaudhary, L. Figueres, and R. J. Wallace. Metabolism of polyunsaturated fatty acids and their toxicity to the microflora of the rumen. *Antonie Leeuwenhoek*, in press.
- McIntosh, F. M., R. J. Wallace, and E. Devillard. 2006. Variations in intermediates and products of linoleic acid biohydrogenation by two different human mixed colonic flora. *Reprod. Nutr. Dev.* **46**(Suppl. 1):S52.
- Mensink, R. P. 2005. Metabolic and health effects of isomeric fatty acids. *Curr. Opin. Lipidol.* **16**:27–30.
- Miller, A., E. McGrath, C. Stanton, and R. Devery. 2003. Vaccenic acid (t11-18:1) is converted to c9,t11-CLA in MCF-7 and SW480 cancer cells. *Lipids* **38**:623–632.
- Moore, W. E. C., J. L. Johnson, and L. V. Holdeman. 1976. Emendation of *Bacteroidaceae* and *Butyrivibrio* and descriptions of *Desulfomonas* gen. nov. and ten new species of the genera *Desulfomonas*, *Butyrivibrio*, *Eubacterium*, and *Ruminococcus*. *Int. J. Syst. Bacteriol.* **26**:238–252.
- Ogawa, J., K. Matsumura, S. Kishino, Y. Omura, and S. Shimizu. 2001. Conjugated linoleic acid accumulation via 10-hydroxy-12-octadecenoic acid during microaerobic transformation of linoleic acid by *Lactobacillus acidophilus*. *Appl. Environ. Microbiol.* **67**:1246–1252.
- Pariza, M. W. 2004. Perspective on the safety and effectiveness of conjugated linoleic acid. *Am. J. Clin. Nutr.* **79**:1132S–1136S.
- Polan, C. E., J. J. McNeill, and S. B. Tove. 1964. Biohydrogenation of unsaturated fatty acids by rumen bacteria. *J. Bacteriol.* **88**:1056–1064.
- Rainio, A., M. Vahvaselka, T. Suomalainen, and S. Laakso. 2001. Reduction of linoleic acid inhibition in production of conjugated linoleic acid by *Propionibacterium freudenreichii* ssp. *shermanii*. *Can. J. Microbiol.* **47**:735–740.
- Rosberg-Cody, E., R. P. Ross, S. Hussey, C. A. Ryan, B. P. Murphy, G. F. Fitzgerald, R. Devery, and C. Stanton. 2004. Mining the microbiota of the neonatal gastrointestinal tract for conjugated linoleic acid-producing bifidobacteria. *Appl. Environ. Microbiol.* **70**:4635–4641.
- Schleifer, K. H., J. Kraus, C. Dvorak, R. Kilpper-Baelz, M. D. Collins, and W. Fischer. 1985. Transfer of *Streptococcus lactis* and related streptococci to the genus *Lactococcus* gen. nov. *Syst. Appl. Microbiol.* **6**:183–195.
- Schleifer, K. H., R. Plapp, and O. Kandler. 1968. Glycine as crosslinking bridge in the LL-diaminopimelic acid containing murein of *Propionibacterium petersonii*. *FEBS Lett.* **1**:287–290.
- Schroepfer, G. J., Jr., W. G. Niehaus, Jr., and J. A. McCloskey. 1970. Enzymatic conversion of linoleic acid to 10D-hydroxy- Δ^{12} -cis-octadecenoic acid. *J. Biol. Chem.* **245**:3798–3801.
- Scollan, N. D., N. J. Choi, E. Kurt, A. V. Fisher, M. Enser, and J. D. Wood. 2001. Manipulating the fatty acid composition of muscle and adipose tissue in beef cattle. *Br. J. Nutr.* **85**:115–124.
- Sharpe, M. E. 1955. A serological classification of lactobacilli. *J. Gen. Microbiol.* **12**:107–122.
- van de Vossenberg, J. L., and K. N. Joblin. 2003. Biohydrogenation of C18 unsaturated fatty acids to stearic acid by a strain of *Butyrivibrio hungatei* from the bovine rumen. *Lett. Appl. Microbiol.* **37**:424–428.
- Wahle, K. W., S. D. Heys, and D. Rotondo. 2004. Conjugated linoleic acids: are they beneficial or detrimental to health? *Prog. Lipid Res.* **43**:553–587.
- Wallace, R. J., L. C. Chaudhary, N. McKain, N. R. McEwan, A. J. Richardson, P. E. Vercoe, N. D. Walker, and D. Paillard. 2006. *Clostridium proteoclasticum*: a ruminal bacterium that forms stearic acid from linoleic acid. *FEMS Microbiol. Lett.* **265**:195–201.
- Wasowska, I., M. R. G. Maia, K. M. Niedzwiedzka, M. Czauderna, J. M. C. Ramalho Ribeiro, E. Devillard, K. J. Shingfield, and R. J. Wallace. 2006. Influence of fish oil on ruminal biohydrogenation of C18 unsaturated fatty acids. *Br. J. Nutr.* **95**:1199–1211.